The effect of penicillamine on blood pressure and vascular disease in mice with infarct-kidney hypertension.
Treatment with penicillamine was capable of bringing down the elevated systemic arterial pressure in the thymus-dependent phase of infarct-kidney hypertension in mice; a marked improvement in the clinical condition of the treated animals was observed as compared with untreated hypertensive mice. No pathological changes in either kidney or heart could be attributed to toxic side effects of penicillamine either in normotensive or in hypertensive mice treated for several months with penicillamine. It is concluded that penicillamine may have an effect on thymus-dependent reactions, such as the increased blood pressure in the chronic phase of infarct-kidney hypertension in mice. In mice, the treatment can be extended over a considerable part of the animal's life span without apparently giving rise to toxic side effects on vital organs.
D000818:Animals; D000906:Antibodies / Q000032:analysis; D003520:Cyclophosphamide / Q000627:therapeutic use; D006977:Hypertension, Renal / Q000188:drug therapy* / Q000473:pathology; D007074:Immunoglobulin G / Q000032:analysis; D007238:Infarction / Q000150:complications* / Q000473:pathology; D007668:Kidney / Q000098:blood supply* / Q000473:pathology; D051379:Mice; D008815:Mice, Inbred Strains; D008819:Mice, Nude; D010396:Penicillamine / Q000627:therapeutic use*; D012710:Serum Albumin, Bovine / Q000276:immunology; D016038:Skin Transplantation; D013950:Thymus Gland / Q000502:physiology* / Q000637:transplantation; D014184:Transplantation, Homologous
D000906:Antibodies; D007074:Immunoglobulin G; D012710:Serum Albumin, Bovine; D003520:Cyclophosphamide; D010396:Penicillamine